Pharmacogenetics in type 2 diabetes: still a conundrum in clinical practice

References

• Eichelbaum M, Evert B. Influence of pharmacogenetics on drug disposition and response. Clin Exp Pharmacol Physiol. 1996;23(10–11):983–985.
   PubMed Web of Science ®Google Scholar
• Prescott LF. Pathological and physiological factors affecting drug absorbtion, distribution, elimination, and response in man. In: Gillette JR, Mitchell JR, eds., From: concepts in biochemical pharmacology. Berlin - Heidelberg: Springer-Verlag; 1975. p. 234–257.
   Google Scholar
• Madian AG, Wheeler HE, Baker Jones R, et al. Relating human genetic variation in drug responses. Trends Genet. 2012;28(10):487–495.
   PubMed Web of Science ®Google Scholar
• Roses AD. Pharmacogenetics and the practice of medicine. Nature. 2000;405(6788):857–865.
   PubMed Web of Science ®Google Scholar
• Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet. 2000;356(9242):1667–1671.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2017;40(Suppl. 1):S11–S24.
   PubMedGoogle Scholar
• IDF Diabetes Atlas – 7th Edition. [cited 2017 Apr 1]. Available from www.diabetesatlas.org
   Google Scholar
• Brunetti A, Brunetti FS, Chiefari E. Pharmacogenetics of type 2 diabetes mellitus: an example of success in clinical and translational medicine. World J Transl Med. 2014;12(3):141–149.
   Google Scholar
• Klonoff DC. Precision medicine for managing diabetes. J Diabetes Sci Technol. 2015;9(1):3–7.
   PubMedGoogle Scholar
• Motsinger-Reif AA, Jorgenson E, Relling MV, et al. Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics. 2013;23(8):383–394.
   PubMed Web of Science ®Google Scholar
• Brunetti A, Chiefari E, Foti D. Perspectives on the contribution of genetics to the pathogenesis of type 2 diabetes mellitus. Recenti Prog Med. 2011;102(12):468–475.
   PubMedGoogle Scholar
• Fuchsberger C, Flannick J, Teslovich TM, et al. The genetic architecture of type 2 diabetes. Nature. 2016;536(7614):41–47.
   PubMed Web of Science ®Google Scholar
• Mohlke KL, Boehnke M. Recent advances in understanding the genetic architecture of type 2 diabetes. Hum Mol Gen. 2015;24(R1):R85–92.
   PubMed Web of Science ®Google Scholar
• Chiefari E, Tanyolaç S, Paonessa F, et al. Functional variants of the HMGA1 gene and type 2 diabetes mellitus. Jama. 2011;305(9):903–912.
   PubMed Web of Science ®Google Scholar
• Maruthur NM, Gribble MO, Bennett WL, et al. The pharmacogenetics of type 2 diabetes: a systematic review. Diabetes Care. 2014;37(3):876–886.
   PubMed Web of Science ®Google Scholar
• Manolopoulos VG, Ragia G, Tavridou A.Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics. 2011;12(8):1161–1191.
   PubMed Web of Science ®Google Scholar
• Pearson ER. Pharmacogenetics in diabetes. Curr Diab Rep. 2009;9(2):172–181.
   PubMed Web of Science ®Google Scholar
• Huang C, Florez JC. Pharmacogenetics in type 2 diabetes: potential implications for clinical practice. Genome Med. 2011;3(11):76.
   PubMed Web of Science ®Google Scholar
• Kleinberger JW, Pollin TI. Personalized medicine in diabetes mellitus: current opportunities and future prospects. Ann N Y Acad Sci. 2015;1346(1):45–56.
   PubMed Web of Science ®Google Scholar
• Flanagan SE, Clauin S, Bellanne-Chantelot C, et al. Update of mutations in the genes encoding the pancreatic beta-cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum Mutat. 2009;30(2):170–180.
   PubMed Web of Science ®Google Scholar
• Pearson ER, Flechtner I, Njolstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med. 2006;355(5):467–477.
   PubMed Web of Science ®Google Scholar
• Pearson ER, Liddell WG, Shepherd M, et al. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes. Diabet Med. 2000;17(7):543–545.
   PubMed Web of Science ®Google Scholar
• Jesic MD, Sajic S, Jesic MM, et al. A case of new mutation in maturity-onset diabetes of the young type 3 (MODY 3) responsive to a low dose of sulphonylurea. Diabetes Res Clin Pract. 2008;81(1):e1–3.
   PubMedGoogle Scholar
• Viollet B, Guigas B, Sanz Garcia N, et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012;122(6):253–270.
   PubMed Web of Science ®Google Scholar
• Todd JN, Florez JC. An update on the pharmacogenomics of metformin: progress, problems and potential. Pharmacogenomics. 2014;15(4):529–539.
   PubMed Web of Science ®Google Scholar
• Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cationic transporter 1 (OCT1) on metformin action. J Clin Invest. 2007;117(5):1422–1431.
   PubMed Web of Science ®Google Scholar
• Zhou K, Donnelly LA, Kimber CH, et al. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes. 2009;58(6):1434–1439.
   PubMed Web of Science ®Google Scholar
• Shu Y, Brown C, Castro RA, et al. Effect of genetic variation in the organic cationic transporter 1, OCT1, on metformin parmacokinetics. Clin Pharmacol Ther. 2008;83(2):273–280.
   PubMed Web of Science ®Google Scholar
• Becker ML, Visser LE, Van Schalk RH, et al. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J. 2009;9(4):242–247.
   PubMed Web of Science ®Google Scholar
• Tkac I, Klimcakova L, Javorsky M, et al. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic type response to metformin in 2 diabetes. Diabetes Obes Metab. 2013;15:189–191.
   PubMed Web of Science ®Google Scholar
• Dujic T, Zhou K, Donnelly LA, et al. Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study. Diabetes. 2015;64(5):1786–1793.
   PubMed Web of Science ®Google Scholar
• Dujic T, Causevic A, Bego T, et al. Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes. Diabet Med. 2016;33(4):511–514.
   PubMed Web of Science ®Google Scholar
• Becker ML, Visser LE, Van Schaik RH, et al. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes. 2009;58(3):745–749.
   PubMed Web of Science ®Google Scholar
• Zhou K, Yee SW, Seiser EL, et al. Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nat Genet. 2016;48(9):1055–1059.
   PubMed Web of Science ®Google Scholar
• Jablonski KA, McAteer JB, De Bakker PI, et al. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes. 2010;59(10):2672–2681.
   PubMed Web of Science ®Google Scholar
• Zhou K, Bellenguez C, Spenser CCA, et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet. 2011;43(2):117–120.
   PubMed Web of Science ®Google Scholar
• Florez JC, Jablonski KA, Taylor A, et al. The C allele of ATM rs11212617 does not associate with metformin response in the diabetes prevention program. Diabetes Care. 2012;35(9):1864–1867.
   PubMed Web of Science ®Google Scholar
• van Leeuwen N, Nijpels G, Becker ML, et al. A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of 5 cohorts. Diabetologia. 2012;55(7):1971–1977.
   PubMed Web of Science ®Google Scholar
• Tkac I. Replication of the association of gene variant near ATM and response to metformin. Pharmacogenomics. 2012;13(12):1331–1332.
   PubMed Web of Science ®Google Scholar
• Ragia G, Petridis I, Tavridou A, et al. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics. 2009;10(11):1781–1787.
   PubMed Web of Science ®Google Scholar
• Holstein A, Hahn M, Patzer O, et al. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. Eur J Clin Pharmacol. 2011;67(5):471–476.
   PubMed Web of Science ®Google Scholar
• Zhou K, Donnelly L, Burch L, et al. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Clin Pharmacol Ther. 2010;87(1):52–56.
   PubMed Web of Science ®Google Scholar
• Schroner Z, Javorsky M, Tkacova R, et al. Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(1):89–91.
   PubMed Web of Science ®Google Scholar
• Holstein A, Hahn M, Körner A, et al. TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. BMC Med Genet. 2011;12:30.
   PubMed Web of Science ®Google Scholar
• Feng Y, Mao G, Ren X, et al. Ser1369Ala variant in sulphonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type e diabetic patients. Diabetes Care. 2008;31(10):1939–1944.
   PubMed Web of Science ®Google Scholar
• Schroner Z, Dobrikova M, Klimcakova L, et al. Variation in KCNQ11 is associated with therapeutic response to sulphonylureas. Med Sci Monit. 2011;17(7):CR392–6.
   PubMed Web of Science ®Google Scholar
• Gloyn AL, Hashim Y, Ashcroft SJ, et al. Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with type 2 diabetes mellitus (UKPDS 53). Diabetes Med. 2001;18(3):206–212.
   PubMed Web of Science ®Google Scholar
• Becker ML, Pearson ER, Tkáč I. Pharmacogenetics of oral antidiabetic drugs. Int J Endocrinol. 2013;2013:686315.
   PubMed Web of Science ®Google Scholar
• Karalliedde J, Buckingham RE. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Saf. 2007;30(9):741–753.
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Roots I, Goldammer M, et al. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet. 2005;44(12):1209–1225.
   PubMed Web of Science ®Google Scholar
• Tomalik-Scharte D, Fuhr U, Hellmich M, et al. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. Drug Metab Dispos. 2011;39(5):927–932.
   PubMed Web of Science ®Google Scholar
• Chen M, Hu C, Jia W. Pharmacogenomics of glinides. Pharmacogenomics. 2015;16(1):45–60.
   PubMed Web of Science ®Google Scholar
• Sathananthan A, Man CD, Micheletto F, et al. Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study. Diabetes Care. 2010;33(9):2074–2076.
   PubMed Web of Science ®Google Scholar
• ‘t Hart LM, Fritsche A, Nijpels G, et al. The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diabetes. 2013;62(9):3275–3281.
   PubMed Web of Science ®Google Scholar
• Chen M, Zhang R, Jiang F, et al. Joint effects of diabetic-related genomic loci on the therapeutic efficacy of oral anti-diabetic drugs in Chinese type 2 diabetes patients. Sci Rep. 2016;6:23266.
   PubMed Web of Science ®Google Scholar